{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:30:14Z","timestamp":1791862214121,"version":"4.3.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"vor","delay-in-days":3780,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2005,8]]},"DOI":"10.1111\/j.1523-1755.2005.00423.x","type":"journal-article","created":{"date-parts":[[2005,7,12]],"date-time":"2005-07-12T18:03:59Z","timestamp":1121191439000},"page":"456-463","source":"Crossref","is-referenced-by-count":32,"title":["Nephroprotection by antifibrotic and anti-inflammatory effects of the vasopeptidase inhibitor AVE7688"],"prefix":"10.1016","volume":"68","author":[{"given":"Oliver","family":"Gross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Louise","family":"Koepke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Beirowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eckhard","family":"Schulze-Lohoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Segerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/j.1523-1755.2005.00423.x_bb0010","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1056\/NEJMe048211","article-title":"Chronic kidney disease predicts cardiovascular disease","volume":"351","author":"Hostetter","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1523-1755.2005.00423.x_bb0015","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1523-1755.2005.00423.x_bb0020","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1523-1755.2005.00423.x_bb0025","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/bmj.321.7274.1440","article-title":"Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The Candesartan and Lisinopril Microalbuminuria (CALM) study","volume":"321","author":"Mogensen","year":"2000","journal-title":"BMJ"},{"key":"10.1111\/j.1523-1755.2005.00423.x_bb0030","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s00467-003-1357-0","article-title":"New perspectives in treatment of glomerulonephritis","volume":"19","author":"Coppo","year":"2004","journal-title":"Pediatr Nephrol"},{"key":"10.1111\/j.1523-1755.2005.00423.x_bb0035","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1161\/01.HYP.0000054215.71691.16","article-title":"Vasopetidase inhibition: A double-edged sword?","volume":"41","author":"Campbell","year":"2003","journal-title":"Hypertension"},{"key":"10.1111\/j.1523-1755.2005.00423.x_bb0040","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1093\/ndt\/16.8.1532","article-title":"Vasopeptidase inhibitors\u2014Concepts and evidence","volume":"16","author":"Ruschitzka","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1523-1755.2005.00423.x_bb0045","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S1471-4892(02)00138-8","article-title":"Vasopeptidase inhibitors: A new class of dual zinc metallopeptidase inhibitors for cardiorenal therapeutics","volume":"2","author":"Molinaro","year":"2002","journal-title":"Curr Opin Pharmacol"},{"key":"10.1111\/j.1523-1755.2005.00423.x_bb0050","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1046\/j.1365-2125.2003.01947.x","article-title":"Vasopeptidase inhibitors: Will they have a role in clinical practice?","volume":"57","author":"Worthley","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/j.1523-1755.2005.00423.x_bb0055","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1161\/01.HYP.0000099240.89890.94","article-title":"Renal effects of omapatrilat and captopril in salt-loaded, nitric oxide-deficient rats","volume":"42","author":"Ying","year":"2003","journal-title":"Hypertension"},{"key":"10.1111\/j.1523-1755.2005.00423.x_bb0060","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1681\/ASN.V12112280","article-title":"Vasopetidase inhibition restores renovascular endothelial dysfunction in salt-induced hypertension","volume":"12","author":"Quaschning","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1523-1755.2005.00423.x_bb0065","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00125-003-1121-9","article-title":"Renoprotective effects of vasopetidase inhibition in an experimental model of diabetic nephropathy","volume":"46","author":"Davis","year":"2003","journal-title":"Diabetologia"},{"key":"10.1111\/j.1523-1755.2005.00423.x_bb0070","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1101\/gad.10.23.2981","article-title":"Collagen COL4A3 knockout: A mouse model for autosomal Alport syndrome","volume":"10","author":"Cosgrove","year":"1996","journal-title":"Genes Dev"},{"key":"10.1111\/j.1523-1755.2005.00423.x_bb0075","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1046\/j.1523-1755.2003.00779.x","article-title":"Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome","volume":"63","author":"Gross","year":"2003","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2005.00423.x_bb0080","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1093\/ndt\/gfh219","article-title":"Antifibrotic, nephroprotective potential of ACE-inhibitor vs AT1-antagonist in a murine model of progressive fibrosis","volume":"19","author":"Gross","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1523-1755.2005.00423.x_bb0085","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1046\/j.1523-1755.2003.00791.x","article-title":"Renoprotection: Clues from knockout models of rare diseases","volume":"63","author":"Abbate","year":"2003","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2005.00423.x_bb0090","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1136\/bmj.1.3454.504","article-title":"Hereditary familial congenital haemorrhagic nephritis","volume":"1","author":"Alport","year":"1927","journal-title":"BMJ"},{"key":"10.1111\/j.1523-1755.2005.00423.x_bb0095","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1523-1755.2004.00712.x","article-title":"DDR1-deficient mice show localized subepithelial GBM thickening with focal loss of slit diaphragms and proteinuria","volume":"66","author":"Gross","year":"2004","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2005.00423.x_bb0100","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0002-9440(10)63152-5","article-title":"CXCR3 is involved in tubulointerstitial injury in human glomerulonephritis","volume":"164","author":"Segerer","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1111\/j.1523-1755.2005.00423.x_bb0105","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1093\/ndt\/17.7.1218","article-title":"Meta-analysis of genotype-phenotype correlation in X-linked Alport syndrome: Impact on genetic counseling","volume":"17","author":"Gross","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1523-1755.2005.00423.x_bb0110","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S0140-6736(98)04433-X","article-title":"Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial","volume":"352","author":"Ruggenenti","year":"1998","journal-title":"Lancet"},{"key":"10.1111\/j.1523-1755.2005.00423.x_bb0115","first-page":"F457","article-title":"ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy","volume":"276","author":"Remuzzi","year":"1999","journal-title":"Am J Physiol"},{"key":"10.1111\/j.1523-1755.2005.00423.x_bb0120","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1681\/ASN.V1341100","article-title":"ACE inhibitors versus AT1 receptor antagonists in patients with chronic renal disease","volume":"13","author":"Hilgers","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1523-1755.2005.00423.x_bb0125","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/hy09t1.094234","article-title":"Angiotensin II and renal fibrosis","volume":"38","author":"Mezzano","year":"2001","journal-title":"Hypertension"},{"key":"10.1111\/j.1523-1755.2005.00423.x_bb0130","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1046\/j.1523-1755.1999.00744.x","article-title":"Role of transforming growth factor-\u03b21 in Alport renal disease progression","volume":"56","author":"Sayers","year":"1999","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2005.00423.x_bb0135","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1172\/JCI119615","article-title":"Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor","volume":"100","author":"Wolf","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1523-1755.2005.00423.x_bb0140","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/S0002-9440(10)64802-X","article-title":"Integrin alpa1beta1 and transforming growth factor-\u03b21 play distinct roles in Alport glomerular pathogenesis and serve as dual targets for metabolic therapy","volume":"157","author":"Cosgrove","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1111\/j.1523-1755.2005.00423.x_bb0145","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0008-6363(03)00544-3","article-title":"Vasopeptidase inhibition prevents nephropathy in Zucker diabetic fatty rats","volume":"60","author":"Schafer","year":"2003","journal-title":"Cardiovasc Res"},{"key":"10.1111\/j.1523-1755.2005.00423.x_bb0150","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s00125-003-1264-8","article-title":"The vasopetidase inhibitor AVE7688 ameliorates type 2 diabetic nephropathy","volume":"47","author":"Schafer","year":"2004","journal-title":"Diabetologia"},{"key":"10.1111\/j.1523-1755.2005.00423.x_bb0155","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ejphar.2003.11.008","article-title":"Chronic vasopeptidase inhibition normalizes diabetic endothelial dysfunction","volume":"484","author":"Schaefer","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"10.1111\/j.1523-1755.2005.00423.x_bb0160","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1046\/j.1523-1755.63.s84.35.x","article-title":"Vasopeptidase inhibition: A new treatment approach for endothelial dysfunction","volume":"63","author":"Quaschning","year":"2003","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2005.00423.x_bb0165","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1046\/j.1523-1755.2003.00871.x","article-title":"Monocytes may promote myofibroblast accumulation and apoptosis in Alport renal fibrosis","volume":"63","author":"Rodgers","year":"2003","journal-title":"Kidney Int"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S008525381550865X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S008525381550865X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,26]],"date-time":"2022-03-26T13:22:25Z","timestamp":1648300945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S008525381550865X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["S008525381550865X"],"URL":"https:\/\/doi.org\/10.1111\/j.1523-1755.2005.00423.x","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2005,8]]}}}